Cumulative Live Birth Rate and Cost-Effectiveness Analysis of Gonadotropin Releasing Hormone-Antagonist Protocol and Multiple Minimal Ovarian Stimulation in Poor Responders

Cumulative Live Birth Rate and Cost-Effectiveness Analysis of Gonadotropin Releasing Hormone-Antagonist Protocol and Multiple Minimal Ovarian Stimulation in Poor Responders

BackgroundThe overall cumulative live birth rate (CLBR) of poor ovarian responders (POR) is extremely low. Minimal ovarian stimulation (MOS) provides a relatively realistic solution for ovarian stimulation in POR. Our study aimed to investigate whether multiple MOS strategies resulted in higher CLBR...

Full description

Bibliographic Details
Main Authors:	Yuan Liu, Rongjia Su, Yu Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-01-01
Series:	Frontiers in Endocrinology
Subjects:	in vitro fertilization poor ovarian responders gonadotropin releasing hormone-antagonist minimal ovarian stimulation cumulative live birth rate
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2020.605939/full

Similar Items

Heterogeneity Among Poor Ovarian Responders According to Bologna Criteria Results in Diverging Cumulative Live Birth Rates
by: Alessia Romito, et al.
Published: (2020-04-01)

Outcomes of High Initial Daily Doses of Gonadotropin in Patients With Poor Ovarian Reserve
by: Li-Ling Chou, et al.
Published: (2010-12-01)

Original delayed-start ovarian stimulation protocol with a gonadotropin-releasing hormone antagonist, medroxyprogesterone acetate, and high-dose gonadotropin for poor responders and patients with poor-quality embryos
by: Kazuhiro Takeuchi, et al.
Published: (2023-10-01)

Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations
by: Ruiqiong Zhou, et al.
Published: (2023-04-01)

Effects of letrozole co-treatment on the cumulative live-birth rate among normal responders in gonadotropin-releasing hormone antagonist cycles
by: Shuyi Zhang, et al.
Published: (2022-12-01)

Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing in vitro Fertilization Treatment: A Randomized Controlled Trial
by: Qiuju Chen, et al.
Published: (2019-11-01)

The earlier the initiation of gonadotropin in poor responders in luteal phase stimulation protocols, the better
by: Jia Huang, et al.
Published: (2022-11-01)

Growth Hormone Supplementation May Not Improve Live Birth Rate in Poor Responders
by: Jinliang Zhu, et al.
Published: (2020-01-01)

The use of gonadotropin-releasing hormone antagonist in women undergoing intrauterine insemination
by: M Yousef Elsemary, et al.
Published: (2019-01-01)

Progestin-primed ovarian stimulation versus GnRH antagonist protocol in poor responders: Risk of premature LH surge and outcome of oocyte retrieval
by: Tzu-Ching Kao, et al.
Published: (2023-01-01)

Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol
by: Behnaz Khani Rabati, et al.
Published: (2012-01-01)

Cumulative Live Birth Rates Following Stimulation With Corifollitropin Alfa Compared With hp-hMG in a GnRH Antagonist Protocol in Poor Ovarian Responders
by: Joaquín Errázuriz, et al.
Published: (2019-03-01)

Comparison of gonadotropin-releasing hormone agonist with GnRH antagonist in polycystic ovary syndrome patients undergoing in vitro fertilization cycle: Retrospective analysis from a tertiary center and review of literature
by: Neeta Singh, et al.
Published: (2014-01-01)

Minimal Stimulation Using Gonadotropin-Releasing Hormone Antagonist is Associated with Higher Live Birth Rates: A National Study of 13,050 Cycles
by: Emily G. Hurley, et al.
Published: (2022-11-01)

Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study
by: Li-Hong Wei, et al.
Published: (2016-02-01)

A novel orally active gonadotropin‐releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology
by: Michiko Hamada, et al.
Published: (2022-01-01)

Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial
by: Yun Wang, et al.
Published: (2018-08-01)

Demographic characteristics and clinical profile of poor responders in IVF / ICSI: A comparative study
by: Nabaneeta Padhy, et al.
Published: (2010-01-01)

Effect of a “Dual Trigger” Using a GnRH Agonist and hCG on the Cumulative Live-Birth Rate for Normal Responders in GnRH-Antagonist Cycles
by: Fumei Gao, et al.
Published: (2021-05-01)

Comparison of the Cumulative Live Birth Rates of Progestin-Primed Ovarian Stimulation and Flexible GnRH Antagonist Protocols in Patients With Low Prognosis
by: Mingze Du, et al.
Published: (2021-09-01)

A premature luteinizing hormone surge without elevated progesterone levels has no adverse effect on cumulative live birth rate in patient undergoing a flexible GnRH antagonist protocol: a retrospective study
by: Yangyang Zhang, et al.
Published: (2023-06-01)

Use of gonadotropins in ovarian stimulation in Spain: Delphi consensus
by: Gorka Barrenetxea, et al.
Published: (2023-12-01)

Cumulative live birth rates between GnRH-agonist long and GnRH-antagonist protocol in one ART cycle when all embryos transferred: real-word data of 18,853 women from China
by: Jingwei Yang, et al.
Published: (2021-08-01)

Live Birth Outcomes for PCOS Patients Under the Follicular-Phase Long-Acting GnRH Agonist Protocol or Antagonist Protocol – A Retrospective Chinese Cohort
by: Zhai J, et al.
Published: (2023-09-01)

Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF
by: Kazuki Nakao, et al.
Published: (2022-01-01)

Dehydroepiandrosterone supplementation and the impact of follicular fluid metabolome and cytokinome profiles in poor ovarian responders
by: Veronique Viardot-Foucault, et al.
Published: (2023-06-01)

Retrospective Analysis of Fresh Single Blastocyst Transfer versus Two Cleavage-Stage Fresh Day-3 Embryo Transfer with High-Quality Embryos during Gonadotropin-Releasing Hormone Antagonist Cycles in High Responders
by: Weijie Xing, et al.
Published: (2023-11-01)

Does the “delayed start” protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial
by: Mahnaz Ashrafi, et al.
Published: (2018-12-01)

Corifollitropin alfa for poor responders patients, a prospective randomized study
by: F. M. Fusi, et al.
Published: (2020-07-01)

Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cycles
by: Shikha Jain, et al.
Published: (2016-01-01)

Flexible Multi-dose GnRH Antagonist versus Long GnRH Agonist Protocol in Poor Responders: A Randomized Controlled Trial
by: Ensieh Shahrokh Tehraninejad, et al.
Published: (2009-02-01)

Early administration of gonadotropin-releasing hormone antagonist versus flexible antagonist ovarian stimulation protocol in poor responders: a randomized clinical trial
by: Tayebeh Esfidani, et al.
Published: (2021-10-01)

Luteal phase stimulation versus follicular phase stimulation in poor ovarian responders: results of a randomized controlled trial
by: Joaquín Llácer, et al.
Published: (2020-02-01)

Dual trigger for final oocyte maturation in expected normal responders with a high immature oocyte rate: a randomized controlled trial
by: Meng-Han Yan, et al.
Published: (2023-10-01)

Clomiphene citrate versus high doses of gonadotropins for <it>in vitro</it> fertilisation in women with compromised ovarian reserve: a randomised controlled non-inferiority trial
by: Ragni Guido, et al.
Published: (2012-12-01)

Rate of rebound in follicle growth after cessation of ovarian stimulation in initial non‐responders: a prospective cohort study
by: Norbert Gleicher, et al.
Published: (2021-01-01)

The Effect of Growth Hormone on the Clinical Outcomes of Poor Ovarian Reserve Patients Undergoing in vitro Fertilization/Intracytoplasmic Sperm Injection Treatment: A Retrospective Study Based on POSEIDON Criteria
by: Mei-hong Cai, et al.
Published: (2019-11-01)

Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer
by: Carsten Gründker, et al.
Published: (2021-02-01)

Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells
by: Kuan-Hao Tsui, et al.
Published: (2014-03-01)

Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria—The Why
by: Sandro C. Esteves, et al.
Published: (2018-08-01)